Qiagen NV
(LTS:0RLT)
€
43.54
0 (0%)
Market Cap: 9.16 Bil
Enterprise Value: 9.58 Bil
PE Ratio: 106.36
PB Ratio: 2.73
GF Score: 85/100 Qiagen NV at Bank of America Merrill Lynch Global Healthcare Conference Transcript
Sep 14, 2022 / 08:00AM GMT
Release Date Price:
€46.46
(-0.96%)
Derik De Bruin
BofA Securities, Research Division - MD of Equity Research
Good evening -- Good afternoon, everyone. Welcome to Bank of America's Global Healthcare Conference. I'm Derik De Bruin, the Senior Life Sciences and Diagnostic Tools Analyst. Our next company today is Qiagen. From Qiagen, we have CFO, Roland Sackers; and we have Head of IR, John Gilardi. Gentlemen, thank you for being here.
Roland Sackers
Qiagen N.V. - CFO, MD & Member of Management Board
Thanks.
Questions & Answers
Derik De Bruin;Roland Sackers
BofA Securities, Research Division - MD of Equity Research;Qiagen N.V. - CFO
I guess to start, what -- sort of like, any opening remarks? It's like -- everybody is obviously worried about demand, say, the businesses, just like any -- you want to sort of like summarize what you saw coming out the second quarter? There was a lot fears in China, there's a lot of fears of stuff like this. Do you want to do some open remarks, so we can start the inquisition?
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot